ProtoKinetix, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SMITH CLARENCE EDWARD, was filed 27 Sept 2024.
ProtoKinetix, Inc.: what insiders have been doing
This page follows insider dealings at ProtoKinetix, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of ProtoKinetix, Inc. in twelve months, the latest record being from 27 September 2024.
The full history, which starts in 2015, counts 200 purchases against 4 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Since the insiders bought
- -41.1%Entry US$0.01 · Close at T+365 US$0.01
- -39.4%Entry US$0.02 · Close at T+365 US$0.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,000,000 shares@ US$0.012.6% of flowCommon StockSEC:0001553350-24-000121:0Canonical exit: 25 Dec 2024 (T+90)
- 3,100,000 shares@ US$0.01Common StockSEC:0001079973-24-000893:1Canonical exit: 12 Sept 2024 (T+90)
- 3,400,000 shares@ US$0.014.5% of flowCommon StockSEC:0001079973-24-000893:0Canonical exit: 11 Sept 2024 (T+90)
- 2,500,000 shares@ US$0.01Common StockSEC:0001079973-24-000553:1Canonical exit: 27 Jun 2024 (T+90)
- 666,667 shares@ US$0.0151.3% of flowCommon StockSEC:0001079973-24-000553:0Canonical exit: 18 Jun 2024 (T+90)
- 7,333,334 shares@ US$0.01514.3% of flowCommon StockSEC:0001079973-23-001824:0Canonical exit: 25 Mar 2024 (T+90)
- 20,000 shares@ US$0.01650.9% of flowCommon StockSEC:0001079973-23-001496:0Canonical exit: 24 Jan 2024 (T+90)
- 1,500,000 shares@ US$0.024.0% of flowCommon StockSEC:0001079973-23-001222:0Canonical exit: 27 Nov 2023 (T+90)
- 2,000,000 shares@ US$0.025.2% of flowCommon StockSEC:0001079973-23-000894:0Canonical exit: 13 Sept 2023 (T+90)
- 3,750,000 shares@ US$0.0210.0% of flowCommon StockSEC:0001079973-23-000780:0Canonical exit: 20 Aug 2023 (T+90)
- 2,000,000 shares@ US$0.025.3% of flowCommon StockSEC:0001079973-23-000147:0Canonical exit: 23 Apr 2023 (T+90)
- 78,400 shares@ US$0.0296Common StockSEC:0001079973-23-000013:1Canonical exit: 15 Mar 2023 (T+90)
- 65,000 shares@ US$0.0306Common StockSEC:0001079973-23-000013:2Canonical exit: 16 Mar 2023 (T+90)
- 100,000 shares@ US$0.033Common StockSEC:0001079973-23-000013:3Canonical exit: 21 Mar 2023 (T+90)
- 1,850,000 shares@ US$0.02Common StockSEC:0001079973-23-000013:4Canonical exit: 30 Mar 2023 (T+90)
- 94,089 shares@ US$0.0240.3% of flowCommon StockSEC:0001079973-23-000013:0Canonical exit: 14 Mar 2023 (T+90)
- 1,125,600 shares0Common StockSEC:0001079973-22-001557:0
- 2,520,000 shares@ US$0.0258.6% of flowCommon StockSEC:0001079973-22-001530:0Canonical exit: 8 Mar 2023 (T+90)
- 3,333,333 shares@ US$0.0314.6% of flowCommon StockSEC:0001079973-22-001315:0Canonical exit: 28 Dec 2022 (T+90)
- 2,666,667 shares@ US$0.0311.4% of flowCommon StockSEC:0001079973-22-000845:0Canonical exit: 9 Oct 2022 (T+90)
- 10,000 shares@ US$0.0491.4% of flowCommon StockSEC:0001079973-22-000596:0Canonical exit: 14 Aug 2022 (T+90)
- 600,000 shares@ US$0.053.9% of flowCommon StockSEC:0001079973-22-000418:0Canonical exit: 28 Jun 2022 (T+90)
- 1,000,000 shares@ US$0.056.5% of flowCommon StockSEC:0001079973-22-000314:0Canonical exit: 16 Jun 2022 (T+90)
- 833,333 shares@ US$0.066.4% of flowCommon StockSEC:0001079973-21-001272:0Canonical exit: 22 Mar 2022 (T+90)
- 1,000 shares@ US$0.150.0% of flowCommon StockSEC:0001079973-21-000883:1Canonical exit: 24 Nov 2021 (T+90)
25 of 217 declarations
About ProtoKinetix, Inc.
ProtoKinetix, Inc. (ticker: PKTX) is a U.S.-listed biotechnology company quoted on the OTC market rather than NYSE/NASDAQ at this stage. Its operating footprint is in the United States, with public business addresses in Ohio, including Dalton and Marietta. The company traces its corporate roots back to 1999, when it was incorporated as RJV Network, Inc.; it adopted the ProtoKinetix name in 2003 and has since repositioned itself around a single scientific platform: AAGP®, a patented anti-aging / anti-freeze glycopeptide designed to support cell survival under stress.
From an analyst’s perspective, ProtoKinetix is best described as a research-and-development stage biotechnology and intellectual-property company rather than a commercial drug manufacturer. Its core efforts are concentrated on developing applications for AAGP® in ophthalmology, dermatology, transplant support, regenerative medicine, and selected biomanufacturing use cases. The company’s business model is therefore highly dependent on scientific validation, partner interest, and the ability to convert preclinical or early-stage research into commercially viable products. This creates a classic niche biotech profile: potentially differentiated technology, but with meaningful execution risk, funding reliance, and long development timelines.
Read moreShow less
ProtoKinetix positions AAGP® as its principal asset and repeatedly highlights laboratory testing, toxicity work, and cell-survival research on its corporate website. The molecule is presented as a small, stable compound inspired by natural biological mechanisms associated with animals that survive extreme cold. The company’s published materials indicate that it has been pursuing the platform for many years and has worked with researchers and advisors to broaden potential applications. However, investors should note that the company’s public disclosures still describe it as a development-stage business, which means there is no broad-scale commercial product revenue base to support valuation today.
Recent corporate news has also been notable on the governance side. In November 2025, ProtoKinetix announced the death of President and CEO Clarence E. Smith and the appointment of Michael Guzzetta as his successor, alongside continued service as CFO, secretary, and treasurer. For market context, PKTX is not currently a NYSE/NASDAQ listing, which is important when assessing liquidity, disclosure depth, and institutional visibility. Overall, ProtoKinetix is a speculative micro-cap biotech story built around a patented cell-survival molecule, with a long operating history, a focused IP platform, and a development pipeline that remains early and partnership-driven.
